Table 4.
Number of poisoning deaths involving NPS by selected drug group, country and year, UK, 2013‐2018
| Year | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2013‐2018 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Country | England and Wales | Northern Ireland | Scotland | UK | England and Wales | Northern Ireland | Scotland | UK | England and Wales | Northern Ireland | Scotland | UK | England and Wales | Northern Ireland | Scotland | UK | England and Wales | Northern Ireland | Scotland | UK | England and Wales | Northern Ireland | Scotland | UK | England and Wales | Northern Ireland | Scotland | UK |
| Drug group | ||||||||||||||||||||||||||||
| Cathinones | 26 | 3 | 4 | 33 | 27 | 8 | 4 | 39 | 49 | 7 | 6 | 62 | 31 | 4 | 1 | 36 | 7 | 4 | 0 | 11 | 16 | 0 | 16 | 156 | 26 | 15 | 197 | |
| Of which, mephedrone | 18 | 0 | 1 | 19 | 22 | 0 | 3 | 25 | 44 | 0 | 2 | 46 | 15 | 0 | 0 | 15 | 1 | 0 | 1 | 2 | 0 | 2 | 102 | 0 | 6 | 108 | ||
| GHB/GBL | 18 | 0 | 0 | 18 | 20 | 1 | 0 | 21 | 26 | 0 | 1 | 27 | 30 | 1 | 0 | 31 | 17 | 0 | 17 | 27 | 0 | 27 | 138 | 2 | 1 | 141 | ||
| Benzodiazepine analogues1 | 3 | 1 | 40 | 44 | 14 | 2 | 44 | 60 | 11 | 1 | 57 | 69 | 10 | 2 | 278 | 290 | 9 | 336 | 345 | 9 | 575 | 584 | 56 | 6 | 1330 | 1392 | ||
| Methiopropamine (MPA) | 4 | 0 | 2 | 6 | 7 | 0 | 5 | 12 | 6 | 0 | 4 | 10 | 10 | 0 | 0 | 10 | 0 | 0 | 0 | 1 | 0 | 1 | 28 | 0 | 11 | 39 | ||
| Alpha‐methyltryptamine (AMT) | 7 | 0 | 3 | 10 | 6 | 0 | 1 | 7 | 5 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 0 | 4 | 22 | ||
| Benzofurans (e.g. 6‐APB) | 7 | 0 | 2 | 9 | 5 | 0 | 0 | 5 | 2 | 0 | 0 | 2 | 3 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 17 | 0 | 2 | 19 | ||
| Novel amphetamines (PMA/PMMA) | 3 | 1 | 9 | 13 | 4 | 4 | 1 | 9 | 1 | 2 | 2 | 5 | 1 | 1 | 2 | 4 | 0 | 0 | 0 | 3 | 1 | 4 | 12 | 8 | 15 | 35 | ||
| Novel opioids | 0 | 0 | 0 | 0 | 4 | 0 | 1 | 5 | 2 | 1 | 0 | 3 | 3 | 0 | 0 | 3 | 2 | 0 | 2 | 11 | 0 | 11 | 22 | 1 | 1 | 24 | ||
| Piperazine derivatives | 1 | 0 | 8 | 9 | 2 | 0 | 1 | 3 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 0 | 11 | 14 | ||
| NBOMes | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 4 | ||
| Synthetic cannabinoids | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 3 | 8 | 1 | 0 | 9 | 27 | 2 | 2 | 31 | 24 | 0 | 24 | 60 | 1 | 61 | 121 | 3 | 4 | 128 | ||
| Other NPS2 | 5 | 0 | 2 | 7 | 5 | 15 | 11 | 31 | 14 | 9 | 5 | 28 | 19 | 3 | 4 | 26 | 2 | 1 | 3 | 0 | 1 | 1 | 45 | 27 | 24 | 96 | ||
| Total from deaths examined | 63 | 4 | 60 | 127 | 82 | 22 | 62 | 166 | 114 | 18 | 74 | 206 | 123 | 10 | 286 | 419 | 61 | 4 | 337 | 402 | 125 | 588 | 713 | 568 | 58 | 1636 | 2262 | |
Note 1. These include alprazolam, delorazepam, diclazepam, etizolam, flubromazepam, phenazepam, etc.
Note 2. These include other substances not included in the categories; these vary between countries and over time.